

R H I N O M E D
ASX:CGP

This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Rhinomed to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection.

Radically improve the way you
breathe,
sleep,
maintain your health and
take medication.

Snapshot

- ⊙ Clear focus on nasal technology
- ⊙ Based on BreatheAssist™ technology platform
- ⊙ First Sports product – *ready to launch*
- ⊙ Sleep (snoring) and Wellbeing product rollout – 2014
- ⊙ Book revenues this calendar year

Board & Management

NON-EXEC CHAIR	<i>Martin Rogers</i>
EXEC DIRECTOR / CEO	<i>Michael Johnson</i>
NON-EXEC DIRECTOR	<i>Lord Simon Reading</i>
CHIEF FINANCIAL OFFICER	<i>Phillip Hains</i>
CHIEF MARKETING OFFICER	<i>Jane Ballantyne</i>

Market Data

(as at 1/10/13)

SHARE PRICE	\$0.039
MARKET CAP	\$13 M
SHARES ON ISSUE	331 M
CASH ON HAND	\$1.54M
BURN RATE	\$57k/pm approx.

Top 5 Shareholders

(as at 8/10/13)

National Nominees	5.83%
Prof Payment Svcs	2.58%
MHBIAT P/L	2.26%
Celtic Cap P/L	2.09%
HSBC Custody Nom	2.05%





TURBINE

MAKE EVERY BREATH COUNT


TURBINE

- ◉ Sits inside the nose
- ◉ Dilates to increase airflow
- ◉ Consumer launch November 2013
- ◉ Manufacturing underway
- ◉ 3 pack @ \$24.95 retail
- ◉ Selling online and through affiliates
- ◉ 18 granted and pending patents
in major jurisdictions
- ◉ Medical grade polymer



TURBINE
increases
airflow,
on average, by
38%*

* Clinical trial - 2005



BREATHEASSIST™ TECHNOLOGY



Dilation can be adjusted on each side of the nose for a comfortable fit

Sits inside the nose and is visually discreet



Patents granted & pending

Applications:

- Sport
- Snoring (nasal congestion)
- Sleep Apnea
- Anxiety, appetite suppression
- Drug delivery (allergy, migraine)

Revenues:

from November 2013

No skin pulling adhesive. Can be re-used

Sits on top of the nose and is not visually discreet

No independent dilation of the nostrils



Patents expired in July 2013

One chance to adhere correctly. Single use only

Applications:

- Sport
- Snoring (nasal congestion)

Revenues:

2006 - US\$100m
2012- est \$145m
Acquired by GSK (2007) - US \$566m

ALL YOU NEED IS AIR.

You don't need fluoro. You need more air.

Turbine is a nasal dilator that increases your air intake by 38%. Which means fewer breaths per minute and a slower heart rate. Just stick it up your nose and get going.

TURBINE. ALL YOU NEED IS AIR

WWW.TURBINE.COM.AU



38%

MORE AIR

You don't need fluoro. You need more air.

Turbine is a nasal dilator that increases your air intake by 38%. Which means fewer breaths per minute and a slower heart rate. Just stick it up your nose and get going.

TURBINE. ALL YOU NEED IS AIR

WWW.TURBINE.COM.AU





4

MILLION

the number of
Australians
who cycle every week¹


\$1

BILLION

the size of the
Australian bike and
accessory market²

¹ AustRoads & the Australian Bicycle Council 2011 ² Bicycle Industries Australia Sept 2011

51 million the number of US Health Club Members²



40 million the number of American Cyclists¹

¹ National Sporting Goods Association 2011

² International Health, Raquet & Sporting Club Association 2012

PRODUCT EXTENTIONS:


SLEEP

WELLBEING


DRUG DELIVERY

Clear & compelling growth strategy


1




2



3




4



WORLDWIDE SLEEP AIDS MARKETS TO REACH \$33.2 BILLION IN 2014

SOURCE: SLEEP AIDS - TECHNOLOGIES AND GLOBAL MARKETS 2010



Summary

- ⊙ Clear focus on proving value of the technology portfolio:
 - Revenues November 2013 - Market launch in Sport
 - Strategic Value - Demonstrate extension into high value markets
- ⊙ Rigorous management of risk
- ⊙ Significant market and KOL strategy in place
- ⊙ Market product extensions (wellbeing & snoring 2014)
- ⊙ New team with strong marketing and commercialisation background to drive commercial success

THETURBINE.COM

C O N T A C T R H I N O M E D

Michael Johnson, Executive Director

mjohnson@rhinomed.com.au

+ 61 (0) 417 395 550

+ 61 (0) 3 9614 3663

Level 9 / 45 William Street
Melbourne VIC 3000